Aflaki E et al. |
Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. |
2014 |
Sci Transl Med |
pmid:24920659
|
Gatt S et al. |
Studies on human acid beta-glucosidase and the nature of the molecular defect in type 1 Ashkenazi Gaucher disease. |
1982 |
Prog. Clin. Biol. Res. |
pmid:6812076
|
Suzuki K |
Glucosylceramide and related compounds in normal tissues and in Gaucher disease. |
1982 |
Prog. Clin. Biol. Res. |
pmid:7122635
|
Sardi SP et al. |
Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. |
2013 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:23297226
|
Dai M et al. |
Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease. |
2016 |
PLoS ONE |
pmid:27598339
|
Sun Y et al. |
Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology. |
2015 |
PLoS ONE |
pmid:25822147
|
Cabrera-Salazar MA et al. |
Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. |
2012 |
PLoS ONE |
pmid:22912851
|
Sun Y et al. |
Substrate compositional variation with tissue/region and Gba1 mutations in mouse models--implications for Gaucher disease. |
2013 |
PLoS ONE |
pmid:23520473
|
Rolfs A et al. |
Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. |
2013 |
PLoS ONE |
pmid:24278166
|
Welford RW et al. |
Plasma lysosphingomyelin demonstrates great potential as a diagnostic biomarker for Niemann-Pick disease type C in a retrospective study. |
2014 |
PLoS ONE |
pmid:25479233
|
Park JK et al. |
Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup. |
2003 |
Pediatr. Res. |
pmid:12595585
|
Orvisky E et al. |
Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation. |
2000 |
Pediatr. Res. |
pmid:10926300
|
Jatana M et al. |
Apoptotic positive cells in Krabbe brain and induction of apoptosis in rat C6 glial cells by psychosine. |
2002 |
Neurosci. Lett. |
pmid:12231442
|
Li YT et al. |
Selective extraction and effective separation of galactosylsphingosine (psychosine) and glucosylsphingosine from other glycosphingolipids in pathological tissue samples. |
2011 |
Neurochem. Res. |
pmid:21136152
|
Schueler UH et al. |
Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. |
2003 |
Neurobiol. Dis. |
pmid:14678774
|
Burrow TA et al. |
CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings. |
2015 |
Mol. Genet. Metab. |
pmid:25219293
|
Orvisky E et al. |
Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. |
2002 |
Mol. Genet. Metab. |
pmid:12208131
|
Tayebi N et al. |
Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? |
2003 |
Mol. Genet. Metab. |
pmid:12809640
|
Xu YH et al. |
Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. |
2011 |
Mol. Genet. Metab. |
pmid:21257328
|
Igisu H et al. |
Inhibition of cytochrome c oxidase and hemolysis caused by lysosphingolipids. |
1988 |
Lipids |
pmid:2840545
|